KR19990071597A - 퀴놀린 유도체 - Google Patents

퀴놀린 유도체 Download PDF

Info

Publication number
KR19990071597A
KR19990071597A KR1019980703873A KR19980703873A KR19990071597A KR 19990071597 A KR19990071597 A KR 19990071597A KR 1019980703873 A KR1019980703873 A KR 1019980703873A KR 19980703873 A KR19980703873 A KR 19980703873A KR 19990071597 A KR19990071597 A KR 19990071597A
Authority
KR
South Korea
Prior art keywords
alkyl
formula
compound
group
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1019980703873A
Other languages
English (en)
Korean (ko)
Inventor
쥬제페 아르날도 마리아 지아르디나
마리오 그루그니
루카 프란세스코 라베글리아
카를로 파리노
Original Assignee
파올로 비지, 엔리꼬 카쭐라니
스미스클라인 비참 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT95MI002461 external-priority patent/IT1276170B1/it
Priority claimed from IT96MI001689 external-priority patent/IT1307331B1/it
Application filed by 파올로 비지, 엔리꼬 카쭐라니, 스미스클라인 비참 에스.피.에이. filed Critical 파올로 비지, 엔리꼬 카쭐라니
Publication of KR19990071597A publication Critical patent/KR19990071597A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1019980703873A 1995-11-24 1996-11-22 퀴놀린 유도체 Withdrawn KR19990071597A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ITMI95A002461 1995-11-24
IT95MI002461 IT1276170B1 (it) 1995-11-24 1995-11-24 Derivati chinolinici
ITMI96A001689 1996-08-02
IT96MI001689 IT1307331B1 (it) 1996-08-02 1996-08-02 Derivati chinolinici
PCT/EP1996/005203 WO1997021680A1 (en) 1995-11-24 1996-11-22 Quinoline derivatives

Publications (1)

Publication Number Publication Date
KR19990071597A true KR19990071597A (ko) 1999-09-27

Family

ID=26331326

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019980703873A Withdrawn KR19990071597A (ko) 1995-11-24 1996-11-22 퀴놀린 유도체

Country Status (26)

Country Link
US (1) US6277862B1 (https=)
EP (1) EP0876347B1 (https=)
JP (1) JP2000501104A (https=)
KR (1) KR19990071597A (https=)
CN (1) CN1207730A (https=)
AP (1) AP9801237A0 (https=)
AR (1) AR004972A1 (https=)
AT (1) ATE289994T1 (https=)
BG (1) BG102558A (https=)
BR (1) BR9611820A (https=)
CA (1) CA2238298A1 (https=)
CZ (1) CZ157998A3 (https=)
DE (1) DE69634416T2 (https=)
EA (1) EA002124B1 (https=)
ES (1) ES2236757T3 (https=)
IL (1) IL124522A0 (https=)
MX (1) MX9804107A (https=)
NO (1) NO311212B1 (https=)
NZ (1) NZ323387A (https=)
OA (1) OA11010A (https=)
PL (1) PL326967A1 (https=)
SK (1) SK66798A3 (https=)
TR (1) TR199800924T2 (https=)
TW (1) TW353066B (https=)
UY (1) UY24733A1 (https=)
WO (1) WO1997021680A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2119155C (en) * 1991-10-18 1999-06-15 Dennis Paul Phillion Fungicides for the control of take-all disease of plants
SE9703407D0 (sv) * 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
GB9825554D0 (en) * 1998-11-20 1999-01-13 Smithkline Beecham Spa Novel Compounds
US7037922B1 (en) 2000-03-10 2006-05-02 Neurogen Corporation Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
JP2002540203A (ja) 1999-03-29 2002-11-26 ニューロゲン コーポレイション Ｎｋ−３および／またはｇａｂａ（ａ）受容体リガンドとしての４−置換キノリン誘導体
WO2000064877A1 (en) 1999-04-26 2000-11-02 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
ES2254688T3 (es) * 2001-04-11 2006-06-16 Glaxosmithkline S.P.A. Derivados de quinolina-4-carboxamida como antagonistas de los receptores nk-3 y nk-2.
AU2002259147A1 (en) * 2001-05-08 2002-11-18 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
SG168407A1 (en) 2003-01-28 2011-02-28 Ironwood Pharmaceuticals Inc Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
GB0303086D0 (en) 2003-02-11 2003-03-19 Merck Sharp & Dohme New compounds
GB0419192D0 (en) 2004-08-27 2004-09-29 Merck Sharp & Dohme Therapeutic agents
AU2005304962B2 (en) * 2004-11-09 2009-11-19 Smithkline Beecham Corporation Glycogen phosphorylase inhibitor compounds and pharmaceutical compositions thereof
GB0425077D0 (en) * 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
GB0515580D0 (en) 2005-07-29 2005-09-07 Merck Sharp & Dohme Therapeutic compounds
JP2009504641A (ja) * 2005-08-11 2009-02-05 アストラゼネカ・アクチエボラーグ Ｎｋ−３受容体の調節剤としてのアルキルピリジルキノリン
AR057130A1 (es) 2005-09-21 2007-11-14 Astrazeneca Ab Quinolinas de alquilsulfoxido y una composicion farmaceutica
TW200804288A (en) * 2005-12-12 2008-01-16 Astrazeneca Ab Alkylsulphonamide quinolines
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2527360B1 (en) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
KR20100075568A (ko) * 2007-09-28 2010-07-02 글락소스미스클라인 엘엘씨 글리코겐 포스포릴라아제 억제제 화합물 및 이의 약제 조성물
KR20100087300A (ko) * 2007-09-28 2010-08-04 글락소스미스클라인 엘엘씨 글리코겐 포스포릴라아제 억제제 화합물 및 이의 약학적 조성물
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
SI2384318T1 (en) 2008-12-31 2018-03-30 Ardelyx, Inc. MEASURES AND PROCEDURES FOR THE INHIBITION OF ANTIPORT INHIBITED BY NHE IN THE TREATMENT OF DISEASES RELATED TO STRENGTH OF FLAMMABILITY OR TRADEMARITY WITH SOLO, AND THE EMISSION OF GASTROINTESTINAL TREATMENT
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
MX366293B (es) 2012-08-21 2019-07-04 Ardelyx Inc Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal.
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
LT2983667T (lt) 2013-04-12 2019-07-10 Ardelyx, Inc. Nhe3 rišantys junginiai ir fosfato pernešimo slopinimo būdai
CA2909752A1 (en) 2013-04-19 2014-10-23 Astrazeneca Ab A nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos)
SI3004138T1 (sl) 2013-06-05 2024-07-31 Bausch Health Ireland Limited Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
WO2017072629A1 (en) 2015-10-29 2017-05-04 Cadila Healthcare Limited Pharmaceutical combination of nk3 receptor antagonist and biguanides
EA201991676A1 (ru) 2017-01-09 2020-01-30 Арделикс, Инк. Ингибиторы nhe-опосредованного антипорта
CA3049678A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2538388B1 (fr) * 1982-12-24 1985-06-21 Pharmuka Lab Nouveaux derives de naphtalene- ou azanaphtalenecarboxamide, leurs procedes de preparation et leur utilisation comme medicaments
JPS6399057A (ja) * 1986-06-27 1988-04-30 Nippon Shinyaku Co Ltd グリシン誘導体
DK0804419T3 (da) * 1994-05-27 2003-11-24 Glaxosmithkline Spa Quinolinderivater som tachykinin NK 3-receptor-antagonister
IT1270615B (it) * 1994-07-14 1997-05-07 Smithkline Beecham Farma Uso di derivati di chinolina

Also Published As

Publication number Publication date
WO1997021680A1 (en) 1997-06-19
NO982331L (no) 1998-07-22
TR199800924T2 (xx) 1998-08-21
NO311212B1 (no) 2001-10-29
CN1207730A (zh) 1999-02-10
DE69634416D1 (de) 2005-04-07
IL124522A0 (en) 1998-12-06
DE69634416T2 (de) 2005-12-29
US6277862B1 (en) 2001-08-21
PL326967A1 (en) 1998-11-09
EA199800477A1 (ru) 1998-12-24
NO982331D0 (no) 1998-05-22
TW353066B (en) 1999-02-21
EP0876347A1 (en) 1998-11-11
AR004972A1 (es) 1999-04-07
ATE289994T1 (de) 2005-03-15
MX9804107A (es) 1998-09-30
BR9611820A (pt) 1999-07-13
BG102558A (bg) 1999-03-31
JP2000501104A (ja) 2000-02-02
AP9801237A0 (en) 1998-06-30
OA11010A (en) 2003-03-06
SK66798A3 (en) 1999-01-11
NZ323387A (en) 2000-02-28
EP0876347B1 (en) 2005-03-02
ES2236757T3 (es) 2005-07-16
CA2238298A1 (en) 1997-06-19
EA002124B1 (ru) 2001-12-24
CZ157998A3 (cs) 1998-12-16
UY24733A1 (es) 2001-08-27

Similar Documents

Publication Publication Date Title
KR19990071597A (ko) 퀴놀린 유도체
WO1997021680A9 (en) Quinoline derivatives
KR19990071598A (ko) 퀴놀린-4-카르복사미드 유도체, 그의 제조 방법 및 뉴로키닌3 (nk-3) 및 뉴로키닌 2 (nk-2) 수용체 길항제로서의 그 용도
EP0804419B1 (en) Quinoline derivatives as tachykinin nk 3 receptor antagonists
US6743804B2 (en) Quinoline derivatives as NK3 antagonists
ES2201509T3 (es) Derivados de quinolina-4-carboxamida como antagonista de los receptores nk-2 y nk-3.
EP1131294B1 (en) Quinoline derivatives as nk-2 and nk-3 receptor ligands
AU757836B2 (en) Quinoline derivatives
AU1031797A (en) Quinoline derivatives
HUP9903427A2 (hu) Kinolinszármazékok, eljárás előállításukra, valamint a vegyületeket tartalmazó gyógyszerkészítmények
NZ500371A (en) NK-2/NK-3 antagonists and their use in treating respiratory disease
Luca et al. PCT WORLD) INTELLECTUAL PROPERTY ORGANIZATION
US20040116469A1 (en) Quinoline-4-carboxamide derivatives as NK-2 and NK-3 receptor antagonists
ITMI961689A1 (it) Derivati chinolinici
AU4263200A (en) Quinoline-4-carboxamide derivatives, their preparation and their use as neurokinin 3 (NK-3)- and neurokinin 2 (NK-2) receptor antagonists
KR20010012823A (ko) Ｎｋ-2 및 ｎｋ-3 수용체 길항제로서의퀴놀린-4-카르복스아미드 유도체
ITMI961688A1 (it) Derivati chinolinici
HK1003884B (en) Quinoline derivatives as tachykinin nk3 receptor antagonists
ITMI972352A1 (it) Derivati chinolinici, procedimento per la loro preparazione e uso come antagonisti del recettore nk3
ITMI952461A1 (it) Derivati chinolinici

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19980523

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid